MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive relationships with investors. In line with the Company’s commitments to better inform and engage with investors and stakeholders, we have launched our interactive investor hub - bringing content and communication into ...

Highlights: Immuron on track to exceed A$7 million in Sales this financial yearUniformed Services University anticipates topline results of Travelan® clinical study in October 2025Immuron anticipates IMM-529 (Clostridiodes difficile infection) IND submission to the FDA in August 2025Launch plans underway for ProIBS® in AustraliaImmuron anticipates IMM-986 (Vancomycin-resistant enterococci) pre-clinical research results in August 2025 MELBOURNE, Australia, May 30, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (AS ...

文章核心观点 - 澳大利亚生物制药公司Immuron与新西兰达成ProIBS®独家分销协议，将在零售药房渠道推出该产品治疗肠易激综合征（IBS）症状，以拓展消化健康产品组合 [1] 公司动态 - Immuron与澳大利亚和新西兰达成ProIBS®独家分销协议，将在零售药房渠道推出该产品治疗IBS症状 [1] - ProIBS®将加入Immuron产品组合，与快速增长的Travelan®品牌共同构建优质功效产品线 [1] - 公司首席商务官表示ProIBS®能为药剂师提供经证实的优质功效产品，为客户带来独特益处 [4] - Calmino集团首席执行官兼创始人很高兴与Immuron展开合作，认为澳新市场潜力大 [5] 行业情况 - IBS是常见消化系统疾病，约每10人中有3人受影响，女性更易患病，症状包括腹痛、腹胀等 [2] - 2025年澳大利亚IBS治疗市场是“消化与肠道药物”市场一部分，预计创收约2.2114亿澳元，年增长率3.28% [2] 产品信息 - ProIBS®是治疗IBS症状的认证医疗器械，含从植物中提取的AVH200®，能支持肠道黏膜屏障 [3] - ProIBS®适合长期使用，安全且无已知药物相互作用 [3] - Calmino集团对1003名用户进行可用性研究，94%的用户认为有帮助，91%的用户生活有改善，98%的用户会推荐给他人 [3]